Can a One-Year bone drug switch beat standard therapy for Steroid-Induced bone loss?
NCT ID NCT07757373
First seen Aug 11, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study follows people with bone loss caused by long-term steroid use to compare two treatment approaches. One group received romosozumab for the first year and then switched to denosumab, while the other group took denosumab throughout. After six years, researchers will measure bone mineral density to see which strategy better preserves bone strength.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Romosozumab followed by denosumab, compared with denosumab alone
- What this could lead to
- If successful, this could show which treatment sequence better preserves bone density over the long term for people on chronic steroids, potentially guiding safer osteoporosis care.
- What could go wrong
- This is a small, extended observation of an earlier trial, not a fresh large study. Results may not apply broadly, and bone density changes do not guarantee fewer fractures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLUCOCORTICOID-ASSOCIATED OSTEOPENIA AND OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tuen Mun Hospital
Hong Kong, Hong Kong